公开(公告)号：US08926994B2

公开(公告)日：2015-01-06

申请号：US13708888

申请日：2012-12-07

Applicant: The Methodist Hospital Research Institute

Inventor： Rita Elena Serda ,  Ismail Mustafa Meraz ,  Jianhua Gu ,  Xiaojun Xia ,  Haifa Shen ,  Tong Sun ,  Mauro Ferrari

IPC: A61K39/00 ,  A61K47/48 ,  A61K9/14

CPC classification number: A61K9/143 ,  A61K39/0011 ,  A61K47/48861 ,  A61K47/48876 ,  A61K47/6923 ,  A61K47/6927 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572

Abstract: Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.

Abstract translation: 公开了包含基于脂质体的第二级颗粒的介孔硅多级载体，以及包含用于各种诊断和治疗适应症的载体的药物组合物和制剂。 在具体实施方案中，提供了包含配体装饰的第二阶段颗粒的MSV用于治疗方法，包括例如治疗哺乳动物癌症，包括人乳腺癌。

公开(公告)号：US20210154141A1

公开(公告)日：2021-05-27

申请号：US17103347

申请日：2020-11-24

Applicant: The Methodist Hospital

Inventor： Rita Elena Serda ,  Ismail Mustafa Meraz

IPC: A61K9/127 ,  C07K17/02 ,  A61K38/18 ,  C07K14/475 ,  C07K14/54 ,  A61K47/69 ,  A61K47/54 ,  A61P35/00 ,  A61K31/7016 ,  A61K38/20

Abstract: Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.

公开(公告)号：US20180243216A1

公开(公告)日：2018-08-30

申请号：US15754206

申请日：2016-08-19

Applicant: The Methodist Hospital

Inventor： Rita Elena Serda ,  Ismail Mustafa Meraz

IPC: A61K9/127 ,  A61P35/00 ,  A61K47/69 ,  A61K38/20 ,  A61K31/7016 ,  A61K47/54

CPC classification number: A61K9/1272 ,  A61K31/7016 ,  A61K38/208 ,  A61K47/544 ,  A61K47/554 ,  A61K47/6911 ,  A61P35/00 ,  C07K17/02

Abstract: Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.

公开(公告)号：US10881612B2

公开(公告)日：2021-01-05

申请号：US15754206

申请日：2016-08-19

Applicant: The Methodist Hospital

Inventor： Rita Elena Serda ,  Ismail Mustafa Meraz

IPC: A61K9/127 ,  A61K38/18 ,  A61K38/20 ,  C07K14/475 ,  C07K14/54 ,  A61K31/7016 ,  C07K17/02 ,  A61K47/69 ,  A61K47/54 ,  A61P35/00

Abstract: Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.

公开(公告)号：US20130195963A1

公开(公告)日：2013-08-01

申请号：US13708888

申请日：2012-12-07

Applicant: The Methodist Hospital Research Institute

Inventor： Rita Elena Serda ,  Ismail Mustafa Meraz ,  Jianhua Gu ,  Xiaojun Xia ,  Haifa Shen ,  Tong Sun ,  Mauro Ferrari

IPC: A61K9/14 ,  A61K39/00

CPC classification number: A61K9/143 ,  A61K39/0011 ,  A61K47/48861 ,  A61K47/48876 ,  A61K47/6923 ,  A61K47/6927 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572

Abstract: Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.

Abstract translation: 公开了包含基于脂质体的第二级颗粒的介孔硅多级载体，以及包含用于各种诊断和治疗适应症的载体的药物组合物和制剂。 在具体实施方案中，提供了包含配体装饰的第二阶段颗粒的MSV用于治疗方法，包括例如治疗哺乳动物癌症，包括人乳腺癌。